Prediction of Drug Response in Gastric Cancer Using 3D Bioprinted In Vitro Tumor Models

What this Trial Is About

Researchers are studying gastric cancer, focusing on how well chemotherapy works for individual patients through a new approach. They are developing three-dimensional bioprinted gastric cancer models from tumor tissues taken during surgery. These lab-grown models will be treated with the same chemotherapy drugs as the patients receive to see if the models can predict how patients respond to treatment. This observational study aims to evaluate whether these 3D tumor models can help forecast chemotherapy effectiveness in gastric cancer. The study involves patients with gastric cancer at different stages: those with resectable stage II/III who will get chemotherapy after surgery, those with locally advanced cancer who will receive chemotherapy before and after surgery, and patients not expected to have chemotherapy before or after surgery. Surgical removal of the tumor is performed, and chemotherapy regimens are guided by clinical experience. The in vitro 3D tumor models will be tested with chemotherapy drugs matching those given to the corresponding patients. Participants will undergo tumor tissue collection during surgery for making the 3D models. Researchers will then compare the drug sensitivity results from these models with the actual clinical response of the patients to chemotherapy over up to two years. The primary outcome is to assess the correlation between drug sensitivity in the lab models and patient response within two weeks from enrollment. Secondary outcomes include monitoring patient responses to adjuvant chemotherapy for up to two years. Patients and their families will provide informed consent and participate in follow-up evaluations as part of this observational study.

Prediction of Drug Response in Gastric Cancer Based on 3D Bioprinting